STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Drug Design & Discovery

RECENT STUDIES OF DRUGS IN TUBERCULOSIS

  1. K. Shanmugapriya
  2. Dr.S. Kameshwaran
  3. S. Shameem
  4. A. Saranya
  5. S.M. Shabariraj
  6. K.P. Sathish

Abstract

The infectious disease tuberculosis (TB), which is brought on by a particular type of bacteria, typically affects the lungs. When infected individuals cough, sneeze, or spit, the virus is disseminated through the air. There are ways to prevent and treat tuberculosis. According to estimates, the TB pathogen has infected around a quarter of the world's population. A cough that lasts longer than three weeks, together with the possibility of phlegm or blood-tinged mucus, are signs of TB. feeling weary or worn out. a fever or sweats during the night.appetite loss. decrease of weight.having a bad overall feeling.It is crucial to comprehend how such subpopulations of M.tb are created during human infection in order to create better medication combinations that efficiently target various mycobacterial phonotypes.

Keywords

References (59)

  1. Wani, Ajaz Ahmed, Ashwani Kumar. Tuberculosis, challenges and status with special reference to Jammu and Kashmir: A way forward. Haya Saudi J Life Sci. 2022; 7(7): 206–209.
  2. Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, et al. Tuberculosis vaccines and prevention of infection. Microbiology and Molecular Biology Reviews. Dec 2014; 78(4): 650–
  3. doi:10.1128/MMBR. 00021-14.
  4. World Health Organization. Implementing the WHO Stop TB Strategy: A handbook for national TB control programmes. Geneva: World Health Organization (WHO); 2008. p. 179.
  5. Harris RE. Epidemiology of Tuberculosis. Epidemiology of chronic disease: global perspectives. Burlington, MA: Jones & Bartlett Learning; 2013. p. 682.
  6. Lawn SD, Zumla AI . Tuberculosis. Lancet. July 2011; 378(9785): 57–72. doi:10.1016/S0140- 6736(10)62173-3.
  7. CDC. (October 2020). Landmark TB trial identifies shorter-course treatment regimen. NCHHSTP Media Team Centers for Disease Control and Prevention.
  8. KD Tripathi. Essential of medical pharmacology . 8th edition. India: Jaypee Brothers Medical Publishers; 2019.
  9. Seung KJ, Keshavjee S, Rich ML.Multidrug -resistant tuberculosis and extensively drug -resistant tuberculosis. Cold Spring Harb. Perspect. Med. 2015 Apr 27; 5(9): a017863. doi:10.1101/cshperspect.a017863.
  10. TB Alliance. (2019). FDA Approves New Treatment for Highly Drug -Resistant Forms of Tuberculosis. [Online] Available at: https://www.tballiance.org/news/fda-approves-new-treatment- highly-drug-resistant-forms- tuberculosis#:~:text=NEW%20YORK%20(August%2014%2C%202019,forms%20of%20tubercu losis%20(TB).
  11. Field SK . Bedaquiline for the treatment of multidrug -resistant tuberculosis: Great promise or disappointment. Therapeutic Advances in Chronic Disease. July 2015; 6(4): 170 –184. doi:10.1177/2040622315582325.
  12. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world’s slow stain: Strategies to beat multidrug -resistant tuberculosis. Science. Mar 2002; 295(5562): 2042 –2046. doi:10.1126/science.1063814.
  13. Centers for Disease Control Prevention (October 2013). Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug -resistant tuberculosis. MMWR. Recommendations and Reports. 62 (RR-09): 1–12.
  14. Worley MV , Estrada SJ. Bedaquiline: A novel antitubercular agent for the treatment of multidrug- resistant tuberculosis. Pharmacotherapy. Nov 2014; 34 (11): 1187–1197. doi:10.1002/phar.1482.
  15. Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D . Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism . Nature Communications. February 2014; 5(1): 3369. doi:10.1038/ncomms4369.
  16. Andries K Verhasselt P Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis . Science. Jan 2005; 307(5707): 223–227. doi:10.1126/science.1106753.
  17. Rustomjee R Diacon AH Allen J , et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. Aug 2008; 52(8): 2831–2835.
  18. Diacon AH, Pym A, Grobusch M , et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. Jun 2009; 360(23): 2397-405. doi:10.1056/NEJMoa0808427.
  19. Janssen Research and Development Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (Bedaquiline): Treatment of Patients With MDR -TB. NDA 204 -384. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti- InfectiveDrugsAdvisoryCommittee/UCM329260.pdf.
  20. Diacon AH, Donald PR, Pym A, et al . Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug -resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. June 2012; 56(6): 3271–6. Recent Studies of Drugs in Tuberculosis Shanmugapriya et al. © STM Journals 2023. All Rights Reserved 21
  21. Drugs.com (2021). Sirturo: Side effects, dosage and uses . [ Online] Drugs.com. Available at: https://www.drugs.com/sirturo.html.
  22. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. Drug - resistant tuberculosis—Current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. May 2012; 205(2): S228–S240. doi:10.1093/infdis/jir858.
  23. Safemedication.com. (2023). Linezolid. [ Online] Available at: https://www.safemedication.com/ drug-library/a/6/0/2/0/a602004.
  24. Nih.gov. (February 2020). DailyMed: Zyvox-linezolid injection, solution Zyvox-linezolid tablet, film coated Zyvox -linezolid suspension . Available at: https://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=6e70e63b-bfd5-478d-a8ee-8ba22c9efabd.
  25. Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ . Linezolid for the treatment of drug-resistant infections. Expert Review of Anti-infective Therapy. Dec 2008; 6(6): 825–848. doi:10.1586/14787210.6.6.825.
  26. Brickner SJ. Oxazolidinone antibacterial agents. Current Pharmaceutical Design. 1996; 2(2): 175–
  27. doi:10.2174/1381612802666220921173820.
  28. Xu GY , Zhou Y , Xu MC. A convenient synthesis of antibacterial linezolid from (S)-glyceraldehyde acetonide (PDF). Chinese Chemical Letters. 2006; 17(3): 302–304.
  29. Diekema DI, Jones RN. Oxazolidinones: A review. Drugs. Jan 2000; 59(1): 7–16.
  30. Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol. May 2001; 41(5): 552–562.
  31. U.S. Food and Drug Administration. (2019). GDUFA implementation. [Online] Available at: https://www.fda.gov/news-events/congressional-testimony/implementation-generic-drug-user-fee- amendments-2012-gdufa.
  32. Welshman IR, Stalker DJ, Wajsczuk CP. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid . Anti-Infect Drugs Chemother. 1998; 16(1):
  33. 31. French Gary. Safety and tolerability of linezolid. Journal of Antimicrobial Chemotherapy. 2003; 51(2): ii45–ii53. doi:10.1093/jac/dkg253.
  34. Parveen Uzma et al. Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis. Indian Journal of Tuberculosis. 2021; 68(1): 106–113.
  35. The Age. (2002). An antibiotic to fight immune bugs. [Online] Available at: https://www.theage.com.au/national/an-antibiotic-to-fight-immune-bugs-20020228-gdu08z.html.
  36. Wilson AP, Cepeda JA, Hayman S, Whitehouse T, Singer M, Bellingan G. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. The Journal of Antimicrobial Chemotherapy. August 2006; 58(2): 470 –473. doi:10.1093/jac/dkl233.
  37. Bozdogan B, Appelbaum PC . Oxazolidinones: Activity, mode of action, and mechanism of resistance. International Journal of Antimicrobial Agents. Feb 2004; 23(2): 113 –119. doi:10.1016/j.ijantimicag.2003.11.003.
  38. U.S. Food and Drug Administration. (2020). FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. [Online] U.S. Food and Drug Administration. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment- resistant-forms-tuberculosis-affects-lungs.
  39. U.S. Food and Drug Administration. (2020). Drug Trials Snapshots: Pretomanid. [Online] Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pretomanid.
  40. TB Alliance. (2014). PA -824 has a New Generic Name: Pretomanid. [Online] Available at: https://www.tballiance.org/news/pa-824-has-new-generic-name-pretomanid.
  41. Lenaerts AJ, Gruppo V , Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM . Preclinical testing of the nitroimidazopyran PA -824 for activity against Research & Reviews: A Journal of Drug Design & Discovery V olume 10, Issue 1 ISSN: 2349-9036 © STM Journals 2023. All Rights Reserved 22 Mycobacterium tuberculosis in a series of in vitro and in vivo models . Antimicrobial Agents and Chemotherapy. June 2005; 49(6): 2294–2301. doi:10.1128/AAC.49.6.2294-2301.2005.
  42. U.S. Food and Drug Administration. (August 2019). Pretomanid FDA label . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/212862Orig1s000ltr.pdf.
  43. Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA . Antitubercular Nitroimidazoles revisited: Synthesis and activity of the authentic 3-Nitro isomer of pretomanid. ACS Med Chem Lett. Nov 2017; 8(12): 1275–1280. doi:10.1021/acsmedchemlett.7b00356.
  44. Connolly Maire, Paul Nunn. Women and tuberculosis. World Health Statistics Quarterly. 1996; 49(2): 115–119.
  45. Lyons MA. Modeling and simulation of pretomanid pharmacokinetics in pulmonary tuberculosis patients. Antimicrob Agents Chemother. Jun 2018; 62(7). doi:10.1128/AAC.02359-17.
  46. Drugs.com. (2022). Pretomanid uses, side effects & warnings. [Online] Drugs.com. Available at: https://www.drugs.com/mtm/pretomanid.html.
  47. Medlineplus.gov. (2022). Tuberculosis. [Online] Available at: https://medlineplus.gov/tuberculosis.html#cat_59.
  48. Skripconoka V , Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V , Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Delamanid improves outcomes and reduces mortality in multidrug -resistant tuberculosis. Eur Respir J. Jun 2013; 41(6): 1393–1400. doi:10.1183/09031936.00125812.
  49. World Health Organization. (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 30–1. WHO technical report series; 994.
  50. JK Aronson. Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2016. p. 284.
  51. Pharmazeutischezeitung: Delamanid: Neuer Wirkstoff gegen multiresistente TB. Archived 2015- 09-24 at the Wayback Machine, 9 May 2014. (in German).
  52. Deltyba INN. Delamanid: European Medicines Agency Europa EU . Available at: https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product- information_en.pdf.
  53. Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug -resistant tuberculosis. Ther Clin Risk Manag. May 2015; 11: 779–791. doi:10.2147/TCRM.S71076.
  54. Alphienes Stanley Xavier, Mageshwaran Lakshmanan. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother . Jul-Sep 2014; 5(3): 222 –224. DOI: 10.4130/ 0976-500X. 136121.
  55. Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug -resistant tuberculosis. Ther Clin Risk Manag. May 2015; 11: 779–791. doi:10.2147/TCRM.S71076.
  56. European Medicines Agency ( EMA). (2018). Deltyba: European Medicines Agency. [Online] Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba.
  57. Katsunori Sasahara, Yoshihiko Shimokawa, Yukihiro Hirao, Noriyuki Koyama, Kazuyoshi Kitano, Masakazu Shibata, Ken Umehara. Pharmacokinetics and metabolism of delamanid, a novel anti- tuberculosis drug, in animals and humans: Importance of albumin metabolism in vivo. Drug Metabolism and Disposition. 2015; 43(8): 1267–1276. doi:10.1124/dmd.115.064527.
  58. Medindia. (2015 ). Delamanid : Side effect(s). [O nline] Available at: https://www.medindia.net/drugs/medication-side-effects/delamanid.htm.
  59. 1mg.com (2022). Delamanid: View uses, side effects and medicines | 1mg. [Online] 1mg. Available at: https://www.1mg.com/generics/delamanid-405151.

You might also find these relevant

Read more of it

Subscribe to one journal or build your own list of several. One invoice, one payment, access for a full year.

Subscribe to journals →

Publish your article

Peer-reviewed journals across every subject, with open access options. Send your manuscript to the right editor today.

Publish with us → Calculate your APC
Support